NCT05164471View on ClinicalTrials.gov

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Hemophilia B
Interventions
GENETIC

verbrinacogene setparvovec

FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B

Trial Locations (7)

33612

University of South Florida, Tampa

48109

University of Michigan, Ann Arbor

90027

Children's Hospital of Los Angeles, Los Angeles

Unknown

Glasgow Royal Infirmary, Glasgow

Guys Hospital, London

Royal Free London NHS Foundation Tust, London

Royal Victoria Infirmary, Newcastle

Sponsors

Lead Sponsor

Spur Therapeutics
All Listed Sponsors
lead

Spur Therapeutics

INDUSTRY

NCT05164471 - Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B | Biotech Hunter | Biotech Hunter